■ Sight Sciences has announced the launch of its next-generation OMNI Surgical System for microinvasive glaucoma surgery (MIGS). The OMNI Surgical System combines 2 distinct angle procedures: ab interno trabeculotomy and transluminal viscoelastic delivery. It allows surgeons to target all 3 points of aqueous humor outflow resistance — TM, Schlemm’s canal, and distal collector channels.

“We designed the next generation of our OMNI Surgical System to provide improved ergonomics, intuitive use, and smooth microcatheter deployment and retraction, while continuing to deliver excellent outcomes as a standalone treatment, or as a procedure performed in conjunction with cataract surgery,” said Sight Sciences chief commercial officer Shawn O’Neil in a news release.

The upgraded system features several updates designed to enhance its ergonomics and usability:

• An updated Luer lock fitting and pull pin to provide increased efficiency in the priming and preparation of the device;
• An ergonomic handle and flexi-grip surface, which fits comfortably and provides stability in the surgeon’s hand; and
• Enhanced gearing and an intuitive wheel design that enable seamless deployment and retraction of the microcatheter.

Initial published results from early use of the OMNI Surgical System show meaningful reductions in IOP and medication use. Several large-scale, multicenter, retrospective, and prospective MIGS clinical studies further evaluating the OMNI Surgical System are under way. The OMNI Surgical System is a tool, not a treatment, and is not specifically cleared by the FDA to lower IOP in patients with open-angle glaucoma.